CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ —
DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the
CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference. The
conference is being held at The Millennium Hotel in New York City. James E.
Brown, DVM, Chief Executive Officer, will be presenting at the conference on
Wednesday, April 30, 2003 at 11:30 a.m. EDT.
A live audio webcast of Dr. Brown’s presentation will be available by
accessing DURECT’s homepage at http://www.www.durect.com and clicking “Investor
Relations.”
DURECT Corporation (www.www.durect.com) is pioneering the development and
commercialization of pharmaceutical systems for the treatment of chronic
debilitating diseases and enabling biotechnology-based pharmaceutical
products. DURECT’s goal is to deliver the right drug to the right site in the
right amount at the right time. In addition to its rights to the
CHRONOGESIC(R) product, DURECT owns three proprietary drug delivery platform
technologies, including the SABER(TM) Delivery System (a patented and
versatile depot injectable useful for protein delivery), the MICRODUR(TM)
Biodegradable Microparticulates (microspheres injectable system) and the
DURIN(TM) Biodegradable Implant (drug-loaded implant system).
NOTE: CHRONOGESIC(R), SABER(TM), MICRODUR(TM) and DURIN(TM) are trademarks
of DURECT Corporation.
The statements in this press release regarding DURECT’s products in
development and product development plans and projected financial results, are
forward-looking statements involving risks and uncertainties that can cause
actual results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, but are not limited to,
DURECT’s ability to complete the design, development, and manufacturing
process development of its products, manufacture and commercialize its
products, obtain product and manufacturing approvals from regulatory agencies,
manage its growth and expenses, manage relationships with third parties,
finance its activities and operations, as well as marketplace acceptance of
DURECT’s products. Further information regarding these and other risks is
included in DURECT’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2002 filed with the SEC on March 14, 2003, DURECT’s Quarterly
Report on Form 10Q and other periodic reports filed with the SEC under the
heading “Factors that may affect future results.”
CHRONOGESIC is under development by DURECT and has not been submitted or
approved for commercialization by the US Food and Drug Administration or other
health authorities.
SOURCE DURECT
CONTACT: Schond L. Greenway, Senior Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417, or
schond.greenway@durect.com/
/Web site: http://www.www.durect.com /
(DRRX)